Entrada Therapeutics, Inc.TRDANASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+28.8%
5Y CAGR+46.5%
Year-over-Year Change
Research and development spending
3Y CAGR
+28.8%/yr
Annual compound
5Y CAGR
+46.5%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
6.7x
Strong expansion
Streak
6 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $142.27M | +13.5% |
| 2024 | $125.31M | +25.5% |
| 2023 | $99.88M | +50.0% |
| 2022 | $66.61M | +85.4% |
| 2021 | $35.93M | +70.2% |
| 2020 | $21.10M | +156.8% |
| 2019 | $8.22M | - |